Loading…
Sonida Senior Living, Inc. owns and operates senior housing communities in the United States. The company provides independent living services, which include daily meals, transportation, social and recreational activities, laundry, housekeeping, and 24-hour staffing; and access to health screenings, periodic special services, and dietary and similar programs, as well as exercise and fitness classes. It offers assisted living services consist of personal care services, such as assistance with activities of daily living, including ambulation, bathing, dressing, eating, grooming, personal hygiene, and monitoring or assistance with medications; support services, such as meals, assistance with social and recreational activities, laundry, general housekeeping, maintenance, and transportation services; and supplemental services, which include extra transportation, personal maintenance, and extra laundry services, as well as special care services for residents with various forms of dementia. In addition, it offers memory care services; and home care services through third-party providers, such as customized physician, dentistry, podiatry, and other health-related rehabilitation and therapy services. Further, it provides respite care and temporary care and therapy programs. The company was formerly known as Capital Senior Living Corporation and changed its name to Sonida Senior Living, Inc. in November 2021. Sonida Senior Living, Inc. was founded in 1990 and is based in Dallas, Texas.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $381M | $23M | $-71M | $-9M | 643445.5% | 25.2% | 3337.5% |
| 2024 | $304M | $78M | $-2M | $-27M | -2.9% | 19.2% | -90.2% |
| 2023 | $255M | $55M | $-21M | $-7M | 18.3% | 7.1% | -61.2% |
| 2022 | $238M | $17M | $-54M | $-27M | 53.5% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 238.43 | 255.32 | 304.33 | 381.14 |
| Operating Revenue | - | 238.43 | 255.32 | 304.33 | 381.14 |
| Cost Of Revenue | - | 27.37 | 21.10 | 33.10 | 44.75 |
| Gross Profit | - | 211.06 | 234.22 | 271.23 | 336.39 |
| Operating Expense | - | 240.37 | 249.41 | 280.19 | 349.84 |
| Selling General And Administration | - | 30.29 | 32.20 | 34.12 | 39.85 |
| Total Expenses | - | 267.74 | 270.51 | 313.29 | 394.59 |
| Operating Income | - | -29.31 | -15.19 | -8.96 | -13.45 |
| EBITDA | - | 17.16 | 55.15 | 78 | 23.24 |
| Normalized EBITDA | - | 19.39 | 24.78 | 35.34 | 52 |
| EBIT | - | -21.29 | 15.26 | 33.95 | -33.53 |
| Interest Income | - | 0.24 | 0.61 | 1.68 | 2.10 |
| Interest Expense | - | 33.02 | 36.12 | 36.99 | 38.64 |
| Net Interest Income | - | -32.79 | -35.51 | -35.31 | -36.53 |
| Other Non Operating Income Expenses | - | 10.01 | -0.53 | -0.54 | 7.95 |
| Other Income Expense | - | 7.78 | 29.84 | 41.23 | -22.18 |
| Interest Income Non Operating | - | 0.24 | 0.61 | 1.68 | 2.10 |
| Interest Expense Non Operating | - | 33.02 | 36.12 | 36.99 | 38.64 |
| Net Non Operating Interest Income Expense | - | -32.79 | -35.51 | -35.31 | -36.53 |
| Pretax Income | - | -54.32 | -20.85 | -3.04 | -72.16 |
| Tax Provision | - | 0.09 | 0.25 | 0.24 | 0.33 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -0.47 | 6.38 | 8.96 | -6.04 |
| Net Income Continuous Operations | - | -54.40 | -21.11 | -3.28 | -72.49 |
| Net Income From Continuing And Discontinued Operation | - | -54.40 | -21.11 | -2.06 | -70.78 |
| Net Income From Continuing Operation Net Minority Interest | - | -54.40 | -21.11 | -2.06 | -70.78 |
| Net Income | - | -54.40 | -21.11 | -2.06 | -70.78 |
| Net Income Common Stockholders | - | -58.97 | -26.10 | -7.58 | -76.42 |
| Net Income Including Noncontrolling Interests | - | -54.40 | -21.11 | -3.28 | -72.49 |
| Normalized Income | - | -52.64 | -45.10 | -35.76 | -48.06 |
| Diluted NI Availto Com Stockholders | - | -58.97 | -26.10 | -7.58 | -76.42 |
| Basic Average Shares | - | 6.36 | 6.79 | 14.11 | 18.09 |
| Diluted Average Shares | - | 6.36 | 6.79 | 14.11 | 18.09 |
| Reconciled Depreciation | - | 38.45 | 39.89 | 44.05 | 56.77 |
| Reconciled Cost Of Revenue | - | 27.37 | 21.10 | 33.10 | 44.75 |
| Total Unusual Items | - | -2.23 | 30.37 | 42.66 | -28.76 |
| Total Unusual Items Excluding Goodwill | - | -2.23 | 30.37 | 42.66 | -28.76 |
| Preferred Stock Dividends | - | 4.57 | 4.99 | 5.52 | 5.64 |
| Minority Interests | - | - | 0 | 1.22 | 1.71 |
| Special Income Charges | - | -2.23 | 30.37 | 42.66 | -28.76 |
| Other Special Charges | -195.30 | 0.64 | -36.34 | -48.54 | - |
| Write Off | 0 | - | - | - | - |
| Impairment Of Capital Assets | - | 1.59 | 5.96 | 0 | 12.52 |
| Restructuring And Mergern Acquisition | - | - | - | 5.87 | 16.23 |
| Depreciation Amortization Depletion Income Statement | - | 38.45 | 39.89 | 44.05 | 56.77 |
| Depreciation And Amortization In Income Statement | - | 38.45 | 39.89 | 44.05 | 56.77 |
| General And Administrative Expense | - | 30.29 | 32.20 | 34.12 | 39.85 |
| Other Gand A | - | 30.29 | 32.20 | 34.12 | 39.85 |
| Salaries And Wages | 2.81 | - | - | - | - |
| Gain On Sale Of Ppe | -0.44 | - | - | - | - |
| Rent Expense Supplemental | 0 | - | - | - | - |
| Other Operating Expenses | - | 171.64 | 177.32 | 202.02 | 253.22 |
| Rent And Landing Fees | 0 | - | - | - | - |
| Otherunder Preferred Stock Dividend | 13.47 | 0 | - | - | - |
| Earnings From Equity Interest | - | - | 0 | -0.90 | -1.37 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Sonida Senior Living, Inc.this co. | SNDA | $1.6B | -22.19 | -142770.48 | 643445.5% | 96.78 |
| Tyra Biosciences, Inc. | TYRA | $1.6B | -13.48 | 6.24 | -46.3% | -11.68 |
| Syndax Pharmaceuticals, Inc. | SNDX | $1.6B | -5.59 | 24.71 | -441.6% | -7.18 |
| Amylyx Pharmaceuticals, Inc. | AMLX | $1.6B | -10.99 | 5.21 | -47.4% | -8.97 |
| agilon health, inc. | AGL |
| - |
| - |
| - |
| - |
| - |
| - |
| $1.6B |
| - |
| 12.54 |
| -308.8% |
| - |
| Nurix Therapeutics, Inc. | NRIX | $1.6B | - | 2.93 | -49.1% | - |
| Vir Biotechnology, Inc. | VIR | $1.5B | - | 2.02 | -57.2% | - |
| ArriVent BioPharma, Inc. | AVBP | $1.5B | - | 5.02 | -54.1% | - |
| PROCEPT BioRobotics Corporation | PRCT | $1.5B | -16.08 | 4.20 | -26.1% | -15.56 |
| Peer Median | - | -12.23 | 5.11 | -51.6% | -10.33 | |